Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 28;38(8):89.
doi: 10.1007/s12032-021-01537-3.

PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer

Meghana Parsi  1 , Milap H Desai  2 , Devashish Desai  3 , Sachi Singhal  3 , Pushti M Khandwala  3 , Rashmika R Potdar  4
Affiliations
Review

PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer

Meghana Parsi et al. Med Oncol. .

Abstract

Although management of advanced prostate cancer is evolving, a lot of work remains to be done for patients who have exhausted all options. Molecular targeting of prostate specific membrane antigen (PSMA) is valuable not only for diagnostic but also for therapeutic reasons. PSMA is thus considered to be useful in a theranostic approach. PSMA scans are upcoming diagnostic modalities which detect metastatic lesions that are missed by conventional imaging modalities. PSMA ligand therapy is also an upcoming treatment modality that has been proven to be beneficial with minimal toxicity in patients with advanced prostate cancer that have progressed on prior therapy. In this review article, we summarize the current knowledge regarding PSMA diagnostics and PSMA ligand therapies and discuss their implication in the treatment of advanced prostate cancer.

Keywords: PSMA; PSMA scans; Prostate cancer; Radioligand; Theranostics.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed - DOI
    1. Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate:ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v69–77. - PubMed - DOI
    1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35. - PubMed
    1. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;57:2321–4. - PubMed
    1. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5. - PubMed

MeSH terms

LinkOut - more resources